acute ischemic stroke
Conditions
Interventions
Sponsors
Cerebrovascular disease center of Changhai
Eligibility
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: intravenous thrombolysis group 1.the treatment could be initiated within 4.5 hours after stroke onset; 2.the candidate should be older than 18 years old and not beyond the birthday of 81 years if administration is started between 3 and 4.5 hours after stroke onset; 3.the existence of any neorological signs that suspected to be acute ischemic stroke. mechanical reperfusion group 1.aged between 18-80 years (i.e. the candidates must not have had their 81th birthday); 2.treatment could be started within 8 hours after onset, or 12 hours for posterior circulation.
Exclusion criteria
Exclusion criteria: intravenous thrombolysis 1.Significant head trauma or prior stroke in previous 3 months; 2.Symptoms suggest subarachnoid hemorrhage; 3.Arterial puncture at noncompressible site in previous 7 days; 4.History of previous intracranial hemorrhage; 5.Intracranial neoplasm, arteriovenous malformation, or aneurysm; 6.Recent intracranial or intraspinal surgery; 7.Elevated blood pressure (systolic higher than 185 mm Hg or diastolic higher than 110 mm Hg); 8.Active internal bleeding; 9.Acute bleeding diathesis; 10.Platelet count less than 100 000/mm3; 11.Heparin received within 48 hours, resulting in abnormally elevated aPTT greater than the upper limit of normal; 12.Current use of anticoagulant with INR more than 1.7 or PT more than 15 seconds; 13.Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevated sensitive laboratory tests (such as aPTT, INR, platelet count, and ECT; TT; or appropriate factor Xa activity assays) 14.Blood glucose concentration less than 50 mg/dL (2.7 mmol/L); 15.CT demonstrates multilobar infarction (hypodensity more than 1/3 cerebral hemisphere); endovascular treatment 1.History stroke or head trauma in the past 3 months; 2.Intracranial neoplasm, arteriovenous malformation or aneurysms; 3.Previous intracranial hemorrhage; 4.Cranial CT reveal hypodensity area larger than 1/3 middle cerebral artery area; 5.Hypertension at the time of treatment; systolic blood pressure (BP) higher than 185 or diastolic pressure higher than 110 mmHg; or aggressive measures to lower BP to below these limits are needed; 6.Any active or recent (within 30 days) hemorrhage; 7.Recent (within 30 days) surgery or biopsy of parenchymal organ; 8.Known coagulation factor deficiency, or oral anticoagulant therapy with INR more than 1.7 or institutionally equivalent prothrombin time longer than 15 seconds; 9.Females of childbearing potential who are known to be pregnant and/or lactating or who have positive pregnancy tests on admission; 10.Baseline lab values: glucose less than 50mg/dl, platelets less than 100 000, or Hct more than 25; 11.Patients who require hemodialysis or peritoneal dialysis; 12.Patients who have received heparin within 48 h must have a normal partial thromboplastin time to be eligible; 13.Subjects with an arterial puncture at a noncompressible site or a lumbar puncture in the previous 7 days 14.Patients with a seizure at the onset of stroke; 15.Other serious, advanced, or terminal illness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| favorable outcome;neurological improvement within 24 hours;rate of symptomatic intracranial hemorrhage; | — |
Secondary
| Measure | Time frame |
|---|---|
| infarction volume;neurological deterioration other than intracranial; | — |
Countries
China
Contacts
Public ContactJianmin LIU
Outcome results
None listed